This Just In…

Two new pharmacy benefit management companies have decided to enter the market, promising to facilitate greater drug price transparency: EmsanaRx and the Mark Cuban Cost Plus Drug Company.

Pharmacy benefit managers (PBMs) work with insurance companies, pharmacies, and manufacturers to negotiate the lowest drug costs for their members. Drug Channels Institute estimates that in 2020 about 77 percent of all prescription claims ran through the top three PBMs — CVS Health, the Express Scripts business of Cigna, and the OptumRx business of UnitedHealth Group.

EmsanaRx is a nonprofit coalition of almost 40 companies planning to offer pharmacy benefit management services to employers. EnsanaRx, which includes retailers such as Walmart and Costco, is the PBM unit of the Purchaser Business Group on Health (PBGH) coalition. Emsana Health plans to serve as an “innovation studio” which will develop new products and solutions with input from PBGH’s employer members.

The goal of the Mark Cuban Cost Plus Drug Company is to sell generic drugs at a transparent, fixed rate, and to unite manufacturing, distribution, and pharmacy services under one roof. The PBM plans to be running by 2023, according to an article in the Wall Street Journal.

Copyright © 2020 Smarts Publishing

About the Author

INSURICA
INSURICA

Share This Story

Stay Updated

Subscribe to the INSURICA blog and receive the latest news direct to your inbox.

Related Blogs

Form 5500 Filing Season: What Employers Should Review Before July 31

June 8th, 2026|Blog, Employee Benefits|

As mid-year approaches, employers sponsoring benefit plans should begin preparing for upcoming Form 5500 filing obligations. For many calendar-year plans, Form 5500 filings are due by July 31, making June an ideal time to confirm whether filing requirements apply and ensure needed information is being gathered.

Pharmacy Costs Are Surging Again — What Employers Can Actually Do in 2026

June 7th, 2026|Blog, Employee Benefits|

Pharmacy spending is once again the fastest growing component of employer health plans. Specialty drugs now account for more than half of total pharmacy spend, and GLP 1 medications for diabetes and weight management are reshaping budgets. Employers are feeling the pressure: rising premiums, unpredictable claims, and employee expectations for access to high cost therapies.

Self Funding for Small and Mid Sized Employers: Why 2026 Is the Breakout Year

June 6th, 2026|Blog, Employee Benefits|

Self funding is no longer just for large employers. In 2026, small and mid sized businesses are embracing level funded and partially self funded plans at record rates. Rising premiums, greater access to stop loss coverage, and improved data analytics are making self funding a viable option for groups as small as 25–50 employees.

Go to Top